NM_198271.5(LMOD3):c.39_41del (p.Leu14del) AND Nemaline myopathy 10

Germline classification:: Benign (1 submission)
Last evaluated:: Jan 29, 2024
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV000549842.8

Allele description [Variation Report for NM_198271.5(LMOD3):c.39_41del (p.Leu14del)]

NM_198271.5(LMOD3):c.39_41del (p.Leu14del)

Genes:

LOC126806710:CDK7 strongly-dependent group 2 enhancer GRCh37_chr3:69170601-69171800 [Gene]
LMOD3:leiomodin 3 [Gene - OMIM - HGNC]

Variant type:

Deletion

Cytogenetic location:

3p14.1

Genomic location:

Preferred name:

NM_198271.5(LMOD3):c.39_41del (p.Leu14del)

HGVS:

NC_000003.12:g.69122348_69122350del
NG_041828.1:g.5248_5250del
NM_001304418.3:c.39_41del
NM_198271.5:c.39_41delMANE SELECT
NP_001291347.1:p.Leu14del
NP_938012.2:p.Leu14del
NP_938012.2:p.Leu14del
NC_000003.11:g.69171497_69171499del
NC_000003.11:g.69171499_69171501del
NM_198271.4:c.39_41del
NM_198271.4:c.39_41delTCT

Protein change:

L14del

Links:

dbSNP: rs139192915

NCBI 1000 Genomes Browser:

rs139192915

Molecular consequence:

NM_001304418.3:c.39_41del - inframe_deletion - [Sequence Ontology: SO:0001822]
NM_198271.5:c.39_41del - inframe_deletion - [Sequence Ontology: SO:0001822]

Condition(s)

Name:: Nemaline myopathy 10 (NEM10)
Identifiers:: MONDO: MONDO:0014513; MedGen: C4015360; OMIM: 616165

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV000655504	Labcorp Genetics (formerly Invitae), Labcorp	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015))	Benign (Jan 29, 2024)	germline	clinical testing	PubMed (1) [See all records that cite this PMID]

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV000655504

Labcorp Genetics (formerly Invitae), Labcorp

criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))

Benign
(Jan 29, 2024)

germline

clinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group, Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]

PMID:: 28492532
PMCID:: PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV000655504.5

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	PubMed (1)

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Sep 29, 2024

ClinVar

Relating variation to medicine